Christopher Ferreri, MD

The faculty consider what level of follow-up they consider meaningful for a one-time therapy, pointing to the International Myeloma Working Group consensus benchmark of sustained minimal residual disease (MRD) negativity with imaging negativity.

The program opens with panelist introductions and an overview of ciltacabtagene autoleucel (ciltacel), a BCMA-directed autologous CAR T-cell therapy given as a single infusion and approved for adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.